Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy

Terra, Steven G., Hamilton, Karen K., Pauly, Daniel F., Lee, Craig R., Herbert Patterson, J., Adams, Kirkwood F., Schofield, Richard S., Belgado, Bernadette S., Hill, James A., Aranda, Juan M., Yarandi, Hossein N., Johnson, Julie A. · 2005 · Pharmacogenetics and Genomics

Abstract

OBJECTIVE: Large variability exists in the improvement in left ventricular (LV) function from beta-blocker treatment. We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the beta1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to beta-blocker therapy among heart failure patients. METHODS: We prospectively enrolled 61 beta-blocker naive patients with systolic heart failure. Patients underwent baseline echocardiography followed by metoprolol CR/XL. The dose was doubled on a biweekly basis up to 200 mg/day or attainment of maximum tolerated dose. Echocardiography was repeated after the patient received the target or highest tolerated dose for 3 months. RESULTS: Among patients with the Arg389Arg genotype, ejection fraction (EF) increased from 23+/-5 to 29+/-10 (P=0.008). Gly389 carriers did not demonstrate any significant change in EF (22+/-9 to 23+/-11; P=0.45). There was a significant between-group difference in EF by genotype (P=0.04). The Arg389Arg genotype was also associated with significantly greater reductions in LV end-diastolic and end-systolic diameters compared to Gly389 carriers. Patients with the Gly49 variant also had a significantly greater reduction in LV end-diastolic diameter compared to Ser49 homozygotes. Multiple regression analysis modeling revealed that the codon 389 polymorphism was a significant predictor of an improvement in EF and both codon 49 and 389 polymorphisms were significant predictors of final LV end-diastolic diameter. CONCLUSIONS: Heart failure patients with the Arg389Arg genotype and Gly49 carriers had greater improvements in LV remodeling from beta-blocker treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01213011-200504000-00006

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 174

Metadata

Authors
Terra, S. G., Hamilton, K. K., Pauly, D. F., Lee, C. R., Herbert Patterson, J., Adams, K. F., Schofield, R. S., Belgado, B. S., Hill, J. A., Aranda, J. M., Yarandi, H. N., & Johnson, J. A.
Venue
Pharmacogenetics and Genomics
Published
2005-04
Volume
15
Issue
4
Pages
227-234
ISSN
1744-6872 (ISSN-L)
OpenAlex
W2084751880
Cited by
174
References
2
FWCI
10.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy. https://app.cochat.ai/papers/10.1097/01213011-200504000-00006
The paper
Terra, S. G., Hamilton, K. K., Pauly, D. F., Lee, C. R., Herbert Patterson, J., Adams, K. F., Schofield, R. S., Belgado, B. S., Hill, J. A., Aranda, J. M., Yarandi, H. N., & Johnson, J. A. (2005). ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy. Pharmacogenetics and Genomics. https://doi.org/10.1097/01213011-200504000-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.